KYORIN Pharmaceutical Co.,Ltd. [4569.T]
TOKYO, May 12 (Pulse News Wire) – Kyorin Pharmaceutical CO.,LTD. (4569.T) unveiled its new mid-term plan, Vision 110-Stage2, targeting growth through 2029.
The strategy focuses on aggressive investment in sustainable growth drivers such as expanding the development pipeline and enhancing high-value drug creation capabilities. Key goals include achieving revenue of ¥126.3 billion by fiscal 2025 and maintaining an operating profit margin of over 20%. Under the plan, KYORIN aims to maximize the penetration of key drugs like Beova and Lasbic while fostering synergies with health-related businesses.
The company also plans significant investments in research and development, aiming to secure major milestones in clinical trials for products like KRP-S and KRP-A. For shareholder returns, KYORIN intends to maintain a dividend payout of ¥56 per share annually while considering increases based on performance and cash flow conditions. The firm prioritizes investments for sustained growth beyond Stage 3.
🟡 Confidence: Standard AI-translated content.